A study on the antiviral drug Paxlovid released last week found the medication is not effective in treating Long COVID.
Research ers, including members of the pharmaceutical giant Pfizer , found taking Paxlovid to be “generally safe,” but noted it “did not show significant benefit in improving fatigue, brain fog, body aches, cardiovascular symptoms, shortness of breath, or gastrointestinal symptoms” associated with Long COVID.
The study also noted a handful of adverse events which occurred during the trial, including patients who reported blood loss anemia, forearm fracture and melanoma, though they were found to be unrelated to the treatment. Seventeen participants reported becoming re-infected with COVID-19 during the study.
Paxlovid research has received billions in taxpayer funding as public health leaders continue to search for a remedy to Long COVID. In February, the Biden administration appropriated $515 million to studying the effects of Long COVID in addition to the already $1.15 billion given in 2020, StatPfizer said in a statement to The National Desk Wednesday further research is required to develop a more effective drug to treat Long COVID.
PAXLOVID remains available for treating eligible patients with COVID-19 who are at high risk for progression to severe illness,” a spokesperson wrote. “The World Health Organization describes PAXLOVID as ‘the best therapeutic choice for high-risk patients to date’ and is a National Institutes of Health-preferred treatment for adult patients at high risk of progressing to severe COVID-19.”before Congress this month on his handling of the coronavirus. Rep. Marjorie Taylor Greene, R-Ga.
Long COVID COVID-19 Study Pfizer Research Treatment Funding
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Pfizer's Paxlovid fails as 15-day treatment for long COVID, study findsA study by Stanford University researchers found that a 15-day course of Pfizer's Paxlovid did not relieve symptoms of long COVID among 155 participants.
Baca lebih lajut »
Extended Course of Paxlovid Adds No Benefit for Those With Long COVIDAn extended course of the antiviral drug Paxlovid won't ease a person's Long COVID symptoms, a new study finds.
Baca lebih lajut »
Scientists Race To Perfect New Oral COVID-19 Treatment Poised To Replace PaxlovidScience, Space and Technology News 2024
Baca lebih lajut »
Pfizer Stock: Chart Indicates a Long-Term Bottom , But Is the Dividend Safe?Stocks Analysis by Brian Gilmartin covering: Pfizer Inc. Read Brian Gilmartin's latest article on Investing.com
Baca lebih lajut »
Pfizer's drug for advanced lung cancer shows promising long-term trial resultsThe company's medicine helped patients live longer without seeing their cancer progress, as most of them experienced that benefit for over five years.
Baca lebih lajut »
Franck Muller’s Goes Long with the Long Island EvolutionFranck Muller—a innovator of many complications—presents a troika expressions of time with the Long Island Evolution collection.
Baca lebih lajut »